KU Cancer Center

We are transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our patient care program

[KU Cancer Center @KUcancercenter]

Our clinical trial leaders gathered with colleagues from around the country this week at the 18th annual @AACI_Cancer Clinical Research Innovation Meeting.

Erin Winters joined a panel on multidisciplinary collaboration, explaining how the cancer center evolved cellular therapy from a hematologic malignancy program into an institution-wide platform.

Thank you Erin and our clinical trial leaders for sharing your insights and fostering collaboration with other cancer centers.
#AACICRI #CRI2026

[KU Cancer Center @KUcancercenter]

At a June 10 event, the Kansas Masonic Foundation honored Roy Jensen, MD, and announced a Distinguished Masonic Professorship in his name.

His leadership helped KU Cancer Center earn NCI comprehensive designation and expand access to care. Read more: https://t.co/RuyNd4WzJe

[KU Cancer Center @KUcancercenter]

What if we could stop cancer before it starts? Join host Dr. Roy Jensen on the Bench to Bedside podcast with guest Dr. Lauren Nye as they explore innovative strategies in cancer prevention clinical trials. Tune in today: https://t.co/ggYGRAtQ1R

[KU Cancer Center @KUcancercenter]

Thank you, @Royals!💙

[Kansas City Royals @Royals]

Recently, the Royals and @KUcancercenter teamed up to host the first annual Royal Resilience luncheon. Five men's cancer survivors, with their caregivers and physicians, were celebrated and honored at Kauffman Stadium. Participants heard from Royals alumni Les Norman and Jeff Montgomery, went on a VIP stadium tour, and played catch on the field with Kyle Isbel. It was a great day!

[University Of Kansas Radiation Oncology @KURadonc]

University of Kansas Medical Center' Ron Chen, MD, MPH, FASCO, FASTRO, Chair, Radiation Oncology, participated in Royal Resilience: Men's Cancer Survivorship Luncheon.
@RonaldChenMD @KUcancercenter @KUMedicine @Royals

[Head For The Cure @HeadfortheCure]

Research fuels progress.💙

Hear from Dr. Akhavan of @KUcancercenter as he shares how research funding from Head for the Cure is helping advance discoveries in brain tumor treatment and care.

Learn more and help bring hope to the brain tumor community:
https://t.co/LQEbPU4hUg

[KU Cancer Center @KUcancercenter]

A new "Triple Threat" CAR T-cell therapy developed at KU Cancer Center is designed to attack three cancer targets at once, potentially overcoming a major challenge in treating blood cancers.

Ramesh Balusu, PhD, scientific director of the Midwest Stem Cell Therapy Center, recently sat down with @SocietyofHemOnc to discuss early results from a phase 1 clinical trial and the benefits of engineering T-cells on-site.

https://t.co/XGGeNHPhdF

[KU Cancer Center @KUcancercenter]

On the latest episode of the Bench to Bedside podcast, Dr. Tara Lin and Dr. Jesus Gonzalez Lugo share an update on #MyeloMATCH, a first-of-its-kind national clinical trial designed to bring precision medicine to patients with #AML. Tune in today: https://t.co/ggYGRAtQ1R

[KU Cancer Center @KUcancercenter]

Teaching Kansas teachers 📝

High school STEM educators recently completed our Professional Development Workshop, equipping them with cancer-focused biology lesson plans.

The unit, Intro to Cancer: Leukemia & Hina’s Story, tells the story of an 11-year-old girl diagnosed with Acute Lymphocytic Leukemia. Students learn about the cell cycle, blood cell differentiation, the immune system and how cancer can disrupt these processes.

[University Of Kansas Radiation Oncology @KURadonc]

Ron Chen, MD, MPH, FASCO, FASTRO, KUMC Rad Onc Chair, presented "Health Related Quality of Life with Pembrolizumab, Results From The AMBASSADOR Randomized Trial (A031501)" at ASCO 2026 Annual Meeting.
@RonaldChenMD @KUcancercenter @KUMedicine @ASCO

[Bret Freudenthal @Freudlab]

That's a wrap on the 25th Annual Midwest DNA Repair Symposium at the University of Kansas Medical Center. Two days, 175 attendees, 4 keynotes, 22 talks, and 85 posters of genuinely incredible science (also some fun socializing of course). I am still smiling, but a bit tired. 🧬🌻

[KU Cancer Center @KUcancercenter]

For #ASCO26 attendees: see “Early results of COMPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer” as part of the Rapid Oral Abstract Session happening at 4:30pm in Hall D1.

[KU Cancer Center @KUcancercenter]

Also in this morning’s poster sessions, melanoma research involving Dr. Gary Doolittle is on display in Hall A at board 249. See “Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma” from 9am-12pm.

[KU Cancer Center @KUcancercenter]

Happy Sunday #ASCO26! Dr. Xinglei Shen will be presenting this morning in Poster Hall A from 9am-12pm. Find him at board 118 to hear about “Image‑only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies”

[KU Cancer Center @KUcancercenter]

Hello #ASCO26 attendees! Find @anup_kasi presenting during this afternoon’s Poster Sessions. From 1:30-4:30pm, he will be at board 149b in Poster Hall A presenting “A late‑phase randomized open‑label multi‑cohort trial to evaluate immune‑related adverse events with different standard‑of‑care dosing strategies of standard‑of‑care immunotherapies: ImmuRAD trial.” What a great team of multidisciplinary researchers represented in that study!

[KU Cancer Center @KUcancercenter]

If you’re attending #ASCO26: Head over to the Arie Crown Theater at 3:57pm where @RonaldChenMD is presenting “Health‑related quality of life (HRQOL) with pembrolizumab or observation for high‑risk muscle‑invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501.)” The Oral Abstract Session starts at 2:45pm.

[KU Cancer Center @KUcancercenter]

Good morning #ASCO26! Later today, don’t miss Dr. Marc Hoffmann presenting “Golcadomide (GOLCA), a potential, first‑in‑class, oral CELMoD + Pola‑RCHP in patients with newly diagnosed aggressive B‑cell lymphoma (a‑BCL): Safety and 12‑month efficacy results.” It’s part of the Rapid Oral Abstract session happening in Room E450a at 1pm.

[KU Cancer Center @KUcancercenter]

Hello #ASCO26! We are excited for this year’s annual meeting and encourage you to follow along using the official conference hashtag. Safe travels to Chicago!

[KU Cancer Center @KUcancercenter]

Led by @KUcancercenter's Dr. Joseph McGuirk and published in @BloodPortfolio's Blood Advances: Allogeneic CD19 CAR T (CTX110) in relapsed/refractory B‑cell NHL showed 65% response and 39% complete response at higher doses, w/a manageable safety profile. https://t.co/qrsi4j3Z7m